Anebulo Pharmaceuticals (ANEB) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Anebulo Pharmaceuticals (NASDAQ: ANEB) is set to release its Q4 2025 earnings on September 24th, with expectations of a loss of ($0.05) per share.
• The company's stock opened at $2.49 and has a market capitalization of approximately $102.29 million, with a 12-month price range between $0.80 and $3.42.
• Following a report on July 23rd, Maxim Group downgraded Anebulo from a "strong-buy" to a "hold" rating, with the stock currently having an average price target of $5.50.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, September 24th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earningresults page for the latest details on the call scheduled for Monday, September 22, 2025 at 4:00 PM ET.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock traded up $0.05 during trading hours on Friday, reaching $2.52. The company had a trading volume of 275,508 shares, compared to its average volume of 125,337. The company has a 50-day moving average price of $2.44 and a 200 day moving average price of $1.67. The firm has a market cap of $103.52 million, a price-to-earnings ratio of -9.69 and a beta of -0.89. Anebulo Pharmaceuticals has a 12-month low of $0.80 and a 12-month high of $3.42.

Wall Street Analyst Weigh In

Separately, Maxim Group cut Anebulo Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $5.50.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 47,954 shares of the company's stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 28.40% of the company's stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.